WELCOME TO
HOT OFF THE BENCH PRESS

We're excited to announce the launch of IDRI's first newsletter, Hot Off the Bench Press! Each issue will highlight the exciting progress we're making towards our goal of bringing scientific innovation from the lab to the people who need it most. We'll also keep you posted on events and updates you won't want to miss, so stay tuned.

IDRI MOVES TO CLINICAL TRIALS WITH VACCINES

After years of preclinical research and development, 2012 will end with three of IDRI's vaccine candidates in Phase 1 clinical trials.

In February, we launched a trial testing our new vaccine candidate against fatal visceral leishmaniasis (VL). Dubbed the parasitic version of HIV/AIDS, VL attacks the immune system by destroying white blood cells, organs and bone marrow. Read more >

With media headlines full of news about the threat of drug-resistant tuberculosis (TB), our move to the clinic to test a TB vaccine is timely. TB has orphaned over 10 million children and costs the global economy $1 billion every single day. Read more >

Our H5N1 influenza vaccine candidate is now in trial. In addition to the traditional needle injection method, this vaccine is also being tested intradermally, using a microneedle that is virtually painless. Read more >

OUR STORIES FROM THE FIELD

On a trip to Ethiopia to continue work on IDRI's diagnostic for leishmaniasis, Rhea Coler, VP of Preclinical Biology, took this photo that highlights the need IDRI is striving to meet.

“This young boy, attended by his father, lies in a hospital bed. They’ve had to travel for days to get to get there, and the boy had an invasive test to determine he has leishmaniasis. He’ll be in the hospital for a month, getting daily injections. His father will stay with him, splitting up his family - another burden of this disease.”

Learn more about IDRI's work in leishmaniasis.

FOLLOW US